Introduction
There are few reports on serum levels of insulin-like growth factor binding protein-6
(IGFBP-6) (1 Serum and Urine Samples Serum samples were obtained from normal subjects, patients with growth hormone deficiency (GHD), acromegaly, and chronic renal failure (CRF). To investigate the effects of IGF-I on serum IGFBP-6, we measured serum IGFBP-6 in normal subjects who received sc administration of IGF-I (0.1 mg/kg) once a day for 7 consecutive days (2). Spot urine samples were collected from two normal adults; 20 mL urine samples were dialyzed against distilled water overnight and lyophilized. The samples were reconstituted with distilled water and then passed through a desalting column (AmpureTM SA). The desalted samples were used for IGFBP-6
Western immunoblot.
Western Immunoblot for IGFBP-6 Serum or urine samples were electrophoresed on 12 % SDS-acrylamide gel under non reducing conditions. The size-fractionated proteins were electroblotted onto a nitrocellulose sheet. The sheet was incubated with anti-IGFBP-6 antibody (Austral Biologicals, CA), washed, and then incubated with horse raddish peroxidase-conjugated anti-rabbit IgG. IGFBP-6-anti-IGFBP-6
antibody complexes were detected with Enhanced Chemiluminescence (ECL) system. normal subjects who received IGF-I for 7 consecutive days were studied to investigate whether GH or IGF-I regulate serum IGFBP-6 levels or not.
Results

Serum
IGFBP-6 Values
When sera from patients with GHD were studied, serum IGFBP-6 did not change before and after GH treatment. Furthermore, serum IGFBP-6 levels did not change after successive adenomectomy in patients with acromegaly and after repetitive IGF-I administration for 7 days in normal adults.
IGFBP-6 Values in Various Clinical Conditions
Compared with the other clinical conditions studied, serum IGFBP-6 levels were remarkably elevated in patients with CRF.
Next we investigated whether increased levels of IGFBP-6 in patients with CRF change either after hemodialysis or renal transplantation.
However, the levels did not change after hemodialysis. However, serum IGFBP-6 levels decreased one day after renal transplantation and decreased further with the improvement in renal function.
Urinary IGFBP-6 IGFBP-6 in urine from normal subjects was studied as we speculated that increased IGFBP-6 levels in CRF might be related to the retention of IGFBP-6 in serum. IGFBP-6 was detected in normal urine samples. 1) Immunoreactive IGFBP-6 was detected at 30 kDa in serum and urine using this systern.
2) Serum IGFBP-6 levels were not GH nor IGF-I dependent.
3) Serum. IGFBP-6 levels remarkably increased in patients with chronic renal failure and the levels did not change after hemodialysis. However, the IGFBP-6 levels dramatically decreased already one day after renal transplantation, and decreased further with the improvement of renal function.
These data indicate that IGFBP-6 might be excreted by the kidneys and serum IGFBP-6 levels might be related to renal function.
